Helping the hurt, without hurting the patient:

safe and effective pain management.

  • 116 million Americans have chronic pain;
  • 50% of these are undertreated;
  • of these, 25% receive no treatment.1,2

Pain management principles

Acetaminophen

  • good first-line "foundational" treatment for most patients.3
  • do not exceed 3 g/day for age >65 (4 g/d for others);
  • caution patients about acetaminophen in OTC and combination products;
  • 650 mg dose is as effective as 1000 mg, with less risk.3

NSAIDs

  • All NSAIDs have similar analgesic efficacy;4
  • to minimize cardiac risk, prescribe naproxen;
  • to minimize GI bleed risk, add a PPI or H2 blocker;
  • celecoxib (Celebrex) has a higher cardiac risk than other NSAIDs; its lower GI risk is negated by aspirin use.

Opiates

  • can be useful when more analgesia is required;
  • sometimes underused;
  • addiction is rare with appropriate use and monitoring.

Drugs for neuropathic pain can be helpful in appropriately selected patients.

Non-pharmacologic therapies, including exercise and weight loss, can reduce the burden of pain.

 

Non-steroidal anti-inflammatory drugs (NSAIDs)

All provide equal pain relief,4 but have different cardiac and GI risk based on degree of COX-1 versus COX-2 inhibition.

Minimizing cardiac risk:

Naproxen (Naprosyn, Aleve, and generics) has the lowest risk of cardiac side effects.

Managing GI toxicity

For patients at increased risk of GI toxicity, add a proton pump inhibitor (PPI) such as omeprazole (Prilosec and generics) or an H2 blocker to the NSAID.6 For those at highest risk of GI side effects, if an NSAID must be used, celecoxib can be combined with a PPI.7

 GI toxicity risk factors:5

  • age >65
  • history of GI bleed or peptic ulcer
  • use of steroids, anticoagulants, or other NSAIDs, including aspirin

NSAIDs and cardioprotective doses of aspirin

Any dose of aspirin will reverse the GI protective effects of celecoxib. For patients who need both a cardioprotective aspirin and an NSAID, prescribe naproxen (with an H2 blocker or PPI to minimize GI risk if needed). Any NSAID should be taken at least 8 hours before or 30 minutes after aspirin to prevent the NSAID from interfering with aspirin’s cardiac benefit.7

 

Sometimes, an opiate is needed

Most opiates have equal analgesic efficacy, adjusting for dose.

  • However, pharmacogenic and other differences among patients can cause different degrees of pain relief and adverse reactions. Of these, differences in codeine metabolism are the most common.

Opiates are very effective in pain relief, but come with important risks.

  • sedation,
  • constipation,
  • confusion,
  • falls and fractures, and
  • addition potential.

Addiction, dependence, and accidental overdose are all potential problems with chronic opiate use.

  • As needed dosing (versus scheduled dosing) and higher doses increase the risk of accidental overdose.8

Reduce risk of opiate misuse with specific prevention measures.9

When starting:

  • Reserve opiates for patients with moderate to severe pain who do not respond to other agents.
  • When considering long-term opiate use, screen for risk of addiction and misuse. This risk is often over-estimated.10
  • Using a medication agreement can help establish a shared understanding of treatment goals and expectations.

During treatment:

  • Regularly reassess pain, adverse effects, and risk of misuse.
  • Use the lowest dose of opiate possible.8
  • Refer to a pain specialist if a patient is not improving or shows evidence of misuse.
  • Use caution when switching between opiate classes; dose conversion charts do not always reflect how variable patient responses will be.

Get ahead of bowel problems. Start a bowel regimen proactively when initiating an opiate.

  • Ask about constipation at follow-up visits.

 

Opiate-like agents

  • tramadol (ultram): short- and long-acting; generics available
  • tapentadol (Nucynta): only short-acting; no generics available (a Schedule II agent)

Both are as effective as other low-potency opiates (e.g. Schedule III agents).11,12


Comments

Opiate-like agents better

   Opiates         better    
Minor side effects opiate-like ages have lower rate of nausea, vomiting, loss of appetite, and dizziness X  
Major side effects opiate-like agents have lower rate of fractures and safety events requiring hospitalization X  

Drug interactions

cannot combine opiate-like agents with any serotenergic agents (TCAs, SNRIs, SSRIs)   X
Contraindications tramadol cannot be used in patients with suicide or seizure risk   X
Long-term safety data

tapentadol was FDA approved 2009

  X
Use in renal or liver impairment tapentadol cannot be used in patients with severe liver or renal impairment   X

 

Neuropathic pain (e.g. diabetic neuropathy, post-herpetic neuralgia, fibromyalgia)

Some anti-convulsants and antidepressants are effective in treating the neuropathic component of pain, though their use is often limited by adverse effects.

  • most common side effects are somnolence, dizziness, and nausea.
  • triyclic antidepressants should be used very carefully and at low dose in the elderly, with regular
    assessments of anti-cholinergic side effects.

Comparative efficacy of selected antidepressants and anti-convulsants in the treatment of diabetic neuropathy.13

Agent (# high quality trials) % pain reduction, compared to placebo Common adverse effects

 Amitriptyline (3)

 

58-63%

dry mouth

urinary retention

hypotension

cardiac conduction abnormality

 Venlafaxine (2)

 Duloxetine (3)

8-23%

decreased appetite

constipation

nausea

vomiting

 Pregablin (4)

 Gabapentin (2)

11-13%

confusion

edema

Combining an opiate with a neuropathic agent in diabetic neuropathy can reduce pain levels better than either drug alone, at low doses.14

 

Other treatments

Other approaches can have modest effects in reducing pain.

 Treatment Advantage Disadvantage
Local steroid injections (joint pain)

injection lasts ~4 weeks

minimal systemic effects

invasive; requires expertise
Local viscosupplement injections (e.g. hyaluronan, joint pain)

injection lasts ~5-13 weeks

minimal systemic effects

invasive; requires expertise

high cost

Topical capsaicin and salicylate products (local superficial pain)

over-the-counter

low cost

minimal systemic effects

may be large placebo component

local skin reactions common
Topical lidocaine patch (local superficial pain) minimal systemic effects

effective only for superficial, not deep pain

not always covered

Topical diclofenac (joint pain)

short-term pain relief (<2 weeks)

minimal side effects

no long-term pain relief

high cost

Glucosamine/chondroitin oral tablets

over-the-counter

low cost

minimally effective

not regulated by the FDA

For many patients with severe degenerative joint disease, replacing a hip or knee can provide substantial relief and end the need for dependence on pain medications. Consider referral to a specialist for worsening DJD.

Non-pharmacologic interventions can also be useful in controlling pain, improving function, or both in osteoarthritis, fibromyalgia, and chronic low back pain.

  Goal
 Condition Pain control Improving function Both
Osteoarthritis quadriceps strengthening weight loss (combined with exercise)

Tai Chi

therapeutic ultrasound

electromagnetic stimulation

braces and insoles

acupuncture

exercise

Fibromyalgia

Cognitive Behavioral Therapy

exercise

acupuncture

_ Tai Chi
Chronic Low Back Pain

spinal manipulation

massage

Cognitive Behavioral Therapy

_ exercise

 

Cost

  • Acetaminophen and most NSAIDs are available OTC or as easily affordable generics.
  • Most long-acting opioids are costly, while many short-acting opiates are available as easily affordable generics.
  • Within agents for neuropathic pain, tricyclic antidepressants are available as affordable generics, but some SNRIs and anti-convulsants are costly.

 

 

References: 1. IOM. Relieving pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. 2011. 2. Won AB, Lapane KL, Vallow S, Schein J, Morris JN, Lipsitz LA. Persistent nonmalignant pain and analgesic prescribing patterns in elderly nursing home residents. J Am Geriatr Soc. Jun 2004;52(6):867-874. 3. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006(1):CD004257. 4. Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008(1):CD000396. 5. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. Mar 27 2007;115(12):1634-1642. 6. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002(4):CD002296. 7. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. May 12 2007;369(9573):1621-1626. 8. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. Apr 6;305(13):1315-1321. 9. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. Feb 2009;10(2): 113-130. 10. Upshur CC, Luckmann RS, Savageau JA. Primary care provider concerns about management of chronic pain in community clinic populations. J Gen Intern Med. Jun 2006;21(6):652-655. 11. Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. Dec 13;170(22):1979-1986. 12. Rodriguez RF, Castillo JM, Castillo MP, et al. Hydrocodone/acetaminophen and tramadol chlorhydrate combination tablets for the management of chronic cancer pain: a doubleblind comparative trial. Clin J Pain. Jan 2008;24(1):1-4. 13. Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ. Jul 14 2007;335(7610):87. 14. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. Mar 31 2005;352(13):1324-1334.